References
- Centers for Disease Control: Classification system for human infections. MMWR 1986; 35: 334–339
- Edelman A. S., Zolla-Pazner S. AIDS: A syndrome of immunedysregula-tion, dysfunction and deficiency. Fed. Am. Soc. Exp. Biol. J. 1989; 322–30
- Hersh E. M., Reuben J. M., Mansell P. W., et al. Immunologic Studies of AIDS: Relationship of immunodeficiency to extent of disease. Ann. N.Y. Acad. Sci. 1984; 437364372
- Weller I. Immunoglobulin subclasses and bacterial infection in anti-HIV positive homosexual men. Vox Sang. 1987; 52: 173–181
- American Foundation for AIDS Research (AmFAR): AIDS/MIV Experimental Treatment Directory (vol. 2, no. 3). AmFAR, New York 1988
- De Simone C., Albertini F., Almaviva M., et al. Clinical and immunolog-ical assessment in HIV+ subjects receiving inosine-pranobex. A randomised, multicentric study. Med. Oncol. Tumor Pharmacother 1989; 1: 63–67
- Lang J. M., Oberling F., Aleksijevic A., et al. Immunomodulation with diethyldithiocarbamate in patients with AIDS-related complex. Lancet 1985; 2: 1066
- De Simone C., Antonaci S., Chirigos M., et al. Report of the Symposium on the Use of Intravenous Gammaglobulin in Adults Infected with the Human Immunodeficiency Virus. J. Clin. Lab. Analysis. 1990; 4: 313–317
- Calvelli T. A., Rubinstein A. Intravenous gamma-globulin in infant acquired immunodeficiency syndrome. Pediatr. Infect. Dis. 1987; 5: S207–210
- Ochs H. D. Intravenous immunoglobulin in the treatment and prevention of acute infections in pediatric acquired immunodeficiency syndrome patients. Pediatr. Infect. Dis. J. 1987; 6: 507–511
- Gupta A., Novik B. E. Rubinstein A: Restoration of suppressor T cell functions in children with AIDS following intravenous gammaglobulin treatment. Am. J. Dis. Child. 1986; 140: 143–146
- De Simone C., Cirelli A., Catania S., et al. Immunopharmacological activity of intravenous gammaglobulins in AIDS and ARC patients. EOS J. Immunol. Immunopharmacol. 1989; 1: 8–11
- Yap P. L., Williams P. E. Immunoglobulin Preparations for HIV-Infected Patients. Vox Sang. 1988; 55: 65–74
- Brunkhorst U., Sturner M., Willers H., et al. Efficacy of Intravenous Imiiunoglobulins in Patients with Advanced HIV-1 Infection. A Randomized Clinical Study. Infection 1990; 18: 2–9
- Pahwa S. Intravenous immune globulin in patients with acquired immune deficiency syndrome. J. Allergy Clin. Immunol. 1989; 4: 625–631
- Fischl M. A., Parker C. B., Pettinelli C., et al. A Randomized controlled trial of a reduced daily dose of zidovudine in patients with the Acquired Immunodeficiency Syndrome. N. E.J. M. 1790; 323: 7009–1014
- Krueger G. R.F. Infectious cofactors in HIV (HI'LV-III/LAV)-positive individuals and their implication for cause and prognosis of acquired immune deficiency. AIDS-Forschung 1986; 21: 125–131
- Schrappe-Bachcr M., Rasokat H., Bauer P., et al. High-dose immunoglobulins in HIV-l-infected adiults with AIDS-related complex and Walter-Reed 5. Vox Sang. 1990; 59: 3–14
- Krueger G. R.F., Ramon A., Degenhardt S., et al. Cellular immunologic parameters in HIV-positive patients with AIDS-related complex and intravenous immunoglobulin therapy. Vox Sang. 1990; 59: 30–37
- Clawson C. C., White J. G. Platelet interaction with bacteria. II. Fate of bacteria. Am. J. Pathol. 1971; 65: 381–175
- Miragliotta G., Lafata M., Jirillo E. Anti-bacterial activity mediated by human platelets. Agents Actions 1988; 25: 401–406
- Tracey K. J., Cerami A. The role of cachectin/Tumor Necrosis Factor in AIDS. Cancer Cells 1987; 1: 62–63
- Jirillo E., Greco B., Munno I., et al. Demonstration of an exaggerated serum release of Tumor Necrosis Factor a and interleukin -1 in HIV-infected patients: a possible correlation with circulating levels of bacterial lipopolysaccharides. “Cellular and molecular aspects of endotoxin reactions”, A. Nowotny, J. J. Spitzer, E. J. Ziegler. Elsevier Science Publisher B.V., Amsterdam 1790; 529–535
- Duth E. J., Maury W. J., Falks T. M., et al. Tumor Necrosis Factor a activates the human immunodeficiency virus type I through induction of nuclear factor binding to the NF-kB sites in the long terminal repeat. Proc. Natl. Acad. Sci. 1989; 86: 5774–5778
- Takaichi S., Masayuki I., Noboru T. Suppression of Tumor Necrosis Factor a Production by a Human Immunoglobulin Preparation for Intravenous Use. Infection Immunity 1990; 5: 1384–1390